Shares of Vitalhub Corp. (TSE:VHI - Get Free Report) have been assigned a consensus rating of "Buy" from the five brokerages that are presently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is C$12.08.
Several analysts have issued reports on the company. Raymond James set a C$13.50 price objective on Vitalhub and gave the company an "outperform" rating in a research note on Thursday, March 27th. TD Securities lifted their target price on shares of Vitalhub from C$13.00 to C$14.00 and gave the stock a "buy" rating in a report on Monday, March 31st. Scotiabank set a C$14.00 price target on shares of Vitalhub and gave the company an "outperform" rating in a report on Thursday, January 30th. Finally, Canaccord Genuity Group boosted their price objective on Vitalhub from C$12.00 to C$12.50 and gave the stock a "buy" rating in a report on Thursday, January 16th.
Get Our Latest Stock Analysis on VHI
Vitalhub Trading Up 2.1 %
Shares of VHI traded up C$0.22 during midday trading on Monday, reaching C$10.85. The stock had a trading volume of 18,423 shares, compared to its average volume of 135,603. The firm has a 50 day simple moving average of C$9.74 and a 200-day simple moving average of C$10.47. The firm has a market cap of C$586.90 million, a PE ratio of 176.47, a P/E/G ratio of 1.18 and a beta of 1.26. Vitalhub has a one year low of C$6.04 and a one year high of C$12.09.
Vitalhub Company Profile
(
Get Free ReportVitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
See Also
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
